Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 191

1.

Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients.

Taly V, Pekin D, Benhaim L, Kotsopoulos SK, Le Corre D, Li X, Atochin I, Link DR, Griffiths AD, Pallier K, Blons H, Bouché O, Landi B, Hutchison JB, Laurent-Puig P.

Clin Chem. 2013 Dec;59(12):1722-31. doi: 10.1373/clinchem.2013.206359. Epub 2013 Aug 12.

2.

The use of COLD-PCR and high-resolution melting analysis improves the limit of detection of KRAS and BRAF mutations in colorectal cancer.

Mancini I, Santucci C, Sestini R, Simi L, Pratesi N, Cianchi F, Valanzano R, Pinzani P, Orlando C.

J Mol Diagn. 2010 Sep;12(5):705-11. doi: 10.2353/jmoldx.2010.100018. Epub 2010 Jul 8.

3.

KRas and BRaf mutational status analysis from formalin-fixed, paraffin-embedded tissues using multiplex polymerase chain reaction-based assay.

Jakubauskas A, Griskevicius L.

Arch Pathol Lab Med. 2010 Apr;134(4):620-4. doi: 10.1043/1543-2165-134.4.620.

PMID:
20367313
4.

Heterogeneity of epidermal growth factor receptor status and mutations of KRAS/PIK3CA in circulating tumor cells of patients with colorectal cancer.

Gasch C, Bauernhofer T, Pichler M, Langer-Freitag S, Reeh M, Seifert AM, Mauermann O, Izbicki JR, Pantel K, Riethdorf S.

Clin Chem. 2013 Jan;59(1):252-60. doi: 10.1373/clinchem.2012.188557. Epub 2012 Nov 7.

5.

Clinical relevance of KRAS-mutated subclones detected with picodroplet digital PCR in advanced colorectal cancer treated with anti-EGFR therapy.

Laurent-Puig P, Pekin D, Normand C, Kotsopoulos SK, Nizard P, Perez-Toralla K, Rowell R, Olson J, Srinivasan P, Le Corre D, Hor T, El Harrak Z, Li X, Link DR, Bouché O, Emile JF, Landi B, Boige V, Hutchison JB, Taly V.

Clin Cancer Res. 2015 Mar 1;21(5):1087-97. doi: 10.1158/1078-0432.CCR-14-0983. Epub 2014 Sep 23.

6.

Cycleave polymerase chain reaction method is practically applicable for V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS)/V-raf murine sarcoma viral oncogene homolog B1 (BRAF) genotyping in colorectal cancer.

Yokota T, Shibata N, Ura T, Takahari D, Shitara K, Muro K, Yatabe Y.

Transl Res. 2010 Aug;156(2):98-105. doi: 10.1016/j.trsl.2010.05.007. Epub 2010 Jun 19.

PMID:
20627194
7.

Optimized allele-specific real-time PCR assays for the detection of common mutations in KRAS and BRAF.

Lang AH, Drexel H, Geller-Rhomberg S, Stark N, Winder T, Geiger K, Muendlein A.

J Mol Diagn. 2011 Jan;13(1):23-8. doi: 10.1016/j.jmoldx.2010.11.007. Epub 2010 Dec 23.

8.

Multiplex detection of KRAS mutations by a matrix-assisted laser desorption/ionization-time of flight mass spectrometry assay.

Choi HS, Min KT, Cha YS, Hong SP.

Clin Biochem. 2014 Aug;47(12):1091-7. doi: 10.1016/j.clinbiochem.2014.03.024. Epub 2014 Apr 12.

PMID:
24726492
9.

A comprehensive procedural approach to genotyping KRAS and BRAF from paraffin embedded tissues for diagnostic purposes.

Palmirotta R, Ludovici G, De Marchis ML, Leone B, Formica V, Ettorre GM, Cavaliere F, Della-Morte D, Ferroni P, Roselli M, Guadagni F.

In Vivo. 2012 Jul-Aug;26(4):537-47.

PMID:
22773565
10.

Next-Generation Genotyping by Digital PCR to Detect and Quantify the BRAF V600E Mutation in Melanoma Biopsies.

Lamy PJ, Castan F, Lozano N, Montélion C, Audran P, Bibeau F, Roques S, Montels F, Laberenne AC.

J Mol Diagn. 2015 Jul;17(4):366-73. doi: 10.1016/j.jmoldx.2015.02.004. Epub 2015 May 5.

PMID:
25952101
11.

Nanofluidic digital PCR for KRAS mutation detection and quantification in gastrointestinal cancer.

Azuara D, Ginesta MM, Gausachs M, Rodriguez-Moranta F, Fabregat J, Busquets J, Pelaez N, Boadas J, Galter S, Moreno V, Costa J, de Oca J, Capellá G.

Clin Chem. 2012 Sep;58(9):1332-41. doi: 10.1373/clinchem.2012.186577. Epub 2012 Jun 27.

12.

Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.

Juanpere N, Agell L, Lorenzo M, de Muga S, López-Vilaró L, Murillo R, Mojal S, Serrano S, Lorente JA, Lloreta J, Hernández S.

Hum Pathol. 2012 Oct;43(10):1573-82. doi: 10.1016/j.humpath.2011.10.026. Epub 2012 Mar 12.

PMID:
22417847
13.

Multiplex PCR/LDR for detection of K-ras mutations in primary colon tumors.

Khanna M, Park P, Zirvi M, Cao W, Picon A, Day J, Paty P, Barany F.

Oncogene. 1999 Jan 7;18(1):27-38.

14.

Sensitive detection of KRAS mutations using enhanced-ice-COLD-PCR mutation enrichment and direct sequence identification.

How Kit A, Mazaleyrat N, Daunay A, Nielsen HM, Terris B, Tost J.

Hum Mutat. 2013 Nov;34(11):1568-80. doi: 10.1002/humu.22427. Epub 2013 Sep 17.

PMID:
24038839
15.

Detection of N-, H-, and KRAS codons 12, 13, and 61 mutations with universal RAS primer multiplex PCR and N-, H-, and KRAS-specific primer extension.

Chang YS, Yeh KT, Hsu NC, Lin SH, Chang TJ, Chang JG.

Clin Biochem. 2010 Feb;43(3):296-301. doi: 10.1016/j.clinbiochem.2009.10.007. Epub 2009 Oct 29.

PMID:
19879255
16.

Genetic analysis of KRAS mutation status in metastatic colorectal cancer patients.

Zavodna K, Konecny M, Krivulcik T, Spanik S, Behulova R, Vizvaryova M, Weismanova E, Galbavy S, Kausitz J.

Neoplasma. 2009;56(3):275-8.

PMID:
19309232
17.

Detection of KRAS Mutations in Circulating Tumor DNA by Digital PCR in Early Stages of Pancreatic Cancer.

Brychta N, Krahn T, von Ahsen O.

Clin Chem. 2016 Nov;62(11):1482-1491. Epub 2016 Sep 2.

18.

Prevalence of KRAS, BRAF, and PIK3CA somatic mutations in patients with colorectal carcinoma may vary in the same population: clues from Sardinia.

Palomba G, Colombino M, Contu A, Massidda B, Baldino G, Pazzola A, Ionta M, Capelli F, Trova V, Sedda T, Sanna G, Tanda F, Budroni M; Sardinian Translational Oncology Group (STOG), Palmieri G, Cossu A, Contu M, Cuccu A, Farris A, Macciò A, Mameli G, Olmeo N, Ortu S, Petretto E, Pusceddu V, Virdis L.

J Transl Med. 2012 Aug 29;10:178. doi: 10.1186/1479-5876-10-178.

19.

Colorectal cancer with mutation in BRAF, KRAS, and wild-type with respect to both oncogenes showing different patterns of DNA methylation.

Nagasaka T, Sasamoto H, Notohara K, Cullings HM, Takeda M, Kimura K, Kambara T, MacPhee DG, Young J, Leggett BA, Jass JR, Tanaka N, Matsubara N.

J Clin Oncol. 2004 Nov 15;22(22):4584-94.

PMID:
15542810
20.

Mutational screening of RET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNB1 in medullary thyroid carcinoma.

Schulten HJ, Al-Maghrabi J, Al-Ghamdi K, Salama S, Al-Muhayawi S, Chaudhary A, Hamour O, Abuzenadah A, Gari M, Al-Qahtani M.

Anticancer Res. 2011 Dec;31(12):4179-83.

PMID:
22199277

Supplemental Content

Support Center